Why CSL Limited shares could be a strong buy today

Is CSL Limited (ASX:CSL) a 'must own' company, or an expensive trap?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healthcare stocks have been a great way to crush the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) over the last few years and I am a big fan of the bigger, globally diversified companies which make up the S&P/ASX 200 Health Care Index (Index: ASX: XHJ).

Blood product company CSL Limited (ASX: CSL) is one of the biggest, but is it still a buy today?

The price of success?

Selling for 27x its trailing earnings, CSL looks slightly more expensive than the average of the S&P/ASX 200 Health Care Index at 23, especially given the company's relatively soft revenue growth of 2% in the 2015 financial year.

What this growth figure hides, however, is a massive return on equity (ROE) from a company absolutely hosing out cash.

Return on equity is hugely important because it measures the return the company generates internally for investors. High returns can be invested back into the company to be compounded year after year, or returned to investors via dividends or share buy-backs.

CSL's return on equity (ROE) for the 2015 financial year was an incredible 50%. This was up 9% from 2014 as the result of a massive AU$950 million on-market share buy-back that reduced the equity in the business, while net profit grew.

CSL Limited 2015 2014 2013 2012 2010
Net Income (US$) 1,379 1,307 1,211 1,024 918
Total equity (US$) 2,746 3,162 3,018 3,477 3,917
ROE 50% 41% 40% 29% 23%

Of course, most companies are financed by a mix of debt and shareholder equity, so it's important to check high return is not a result of the company loading up on debt, which is a potential risk for shareholders. At 30 June 2015 CSL had a debt-to-equity ratio of 1.3x which is similar to Cochlear Limited (ASX: COH) and seems appropriate given the strong cash flow.

The other question we need to ask is if the high ROE is sustainable, to allow compounding over time. CSL holds a huge number of patents over its products, which act as a competitive advantage over competitors, while the company's recent run of strong returns on equity per the table above also adds confidence.

Is CSL a buy today?

Buoyed by a strong line of products and a growing market, in my view CSL has a lot of potential to continue to compound and deliver high returns to investors. So long as product quality is maintained and debt is managed, I would be very happy to own CSL today.

Motley Fool contributor Regan Pearson has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »